Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Surgery Partners (SGRY) EBITDA: 2013-2024

Historic EBITDA for Surgery Partners (SGRY) over the last 11 years, with FY2024 value amounting to $493.6 million.

  • Surgery Partners' EBITDA rose 7356.32% to $105.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.4 million, marking a year-over-year increase of 2578.15%. This contributed to the annual value of $493.6 million for FY2024, which is 1197.82% up from last year.
  • Per Surgery Partners' latest filing, its EBITDA stood at $493.6 million for FY2024, which was up 1197.82% from $440.8 million recorded in FY2023.
  • Surgery Partners' EBITDA's 5-year high stood at $493.6 million during FY2024, with a 5-year trough of $273.5 million in FY2020.
  • Its 5-year average for EBITDA is $412.4 million, with a median of $440.8 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 1114.36% in 2020, then soared by 4504.57% in 2021.
  • Over the past 5 years, Surgery Partners' EBITDA (Annual) stood at $273.5 million in 2020, then soared by 45.05% to $396.7 million in 2021, then rose by 15.28% to $457.3 million in 2022, then fell by 3.61% to $440.8 million in 2023, then rose by 11.98% to $493.6 million in 2024.
  • Its EBITDA stands at $493.6 million for FY2024, versus $440.8 million for FY2023 and $457.3 million for FY2022.